Some providers featured on this site may compensate us. This may affect the order and placement of listings but does not influence our editorial ratings or reviews.
Treatments Hub

Verified prices

All verified prices
Guide8 min read

Lost Coverage for Zepbound or Wegovy? Your Options (2026)

When a plan drops Zepbound or Wegovy, five routes remain: appeal, manufacturer savings, Medicare's $50 option, brand-name cash by telehealth, or compounded.

Updated October 8, 2026

Medically reviewed on

How we review

The quick answerFive routes: appeal if the drug is still on your formulary; use the manufacturer's savings card or direct price (Foundayo lists $149-$349 a month self-pay, $25 with commercial insurance); if you're on Medicare, the GLP-1 Bridge pilot charges a flat $50 a month for Wegovy, the Zepbound KwikPen and Foundayo through December 2027; buy brand-name for cash through telehealth ($1,149-$1,799 a month); or switch to a compounded version at $41-$299 a month. A licensed clinician decides whether your dose transfers.Prices verified on each provider’s site as of November 18, 2026.

Key takeaways

  • Losing coverage for a weight-loss GLP-1 is common: many plans cover these drugs for diabetes but not for weight management, and prior-authorization denials and formulary changes happen mid-treatment.
  • Five routes remain. Appeal or re-authorize. Use the manufacturer's savings card or direct-pay price (Foundayo lists $149-$349 a month self-pay; $25 with commercial insurance). If you are on Medicare, the GLP-1 Bridge pilot charges a flat $50 a month for Wegovy, Zepbound KwikPen and Foundayo through December 2027. Buy brand-name for cash through telehealth ($1,149-$1,799 a month at the providers we track). Or switch to a compounded version at $41-$299 a month.
  • Switching routes does not have to mean restarting your dose - but only a licensed clinician can transfer a dose, and compounded products are not FDA-approved.
  • Prices are the providers' and manufacturers' own published figures at our last verification; program rules change, so re-check before deciding.

What exactly did you lose: a denial or a formulary change?

The short answerFive routes remain when a plan drops Zepbound or Wegovy. Appeal or re-authorize. Use the manufacturer's savings card or direct-pay price, with Foundayo listed at $149 to $349 a month self-pay. If you are on Medicare, the GLP-1 Bridge pilot charges a flat $50 a month for Wegovy, the Zepbound KwikPen and Foundayo through December 2027. Buy brand-name for cash through telehealth at $1,149 to $1,799 a month. Or switch to a compounded version at $41 to $299 a month, which is not an FDA-approved product. Only a licensed clinician can transfer your dose.
A denial letter and a formulary change are different problems. A prior-authorization denial means the drug is on your plan but you didn't meet its criteria - BMI thresholds, documented conditions, a prior program - and can often be appealed with better documentation from your prescriber. A formulary exclusion means your plan no longer covers the drug for weight management at all, and no appeal fixes that; you need a different route. A plan change at work or through a new year is the same as an exclusion until proven otherwise. Our guide to GLP-1s with insurance walks through reading the formulary and the appeal; the rest of this page is for when the answer is no.

Our top 2 picks

Our two recommended GLP-1 providers, shown with the same verified pricing and ratings as our full comparison.

Our Top Pick
1
embody logo

Exceptional

9.8out of 10

Compounded GLP-1 from $49/month; not FDA-approved, free expedited delivery

Free expedited deliveryNo hidden fees
  • Compounded semaglutide ($49/mo) and tirzepatide ($99/mo) as shown on the homepage, Nov 16, 2026; not FDA-approved
  • Online intake, then a prescriber review by OpenLoop Health, a network of US-licensed doctors
  • Free expedited delivery (embody's words); the Terms do not guarantee a delivery timeline
  • No insurance required, no clinic visits; cancel at least 72 hours before the next billing date

from $49/month

Doctor-prescribed compounded GLP-1 treatment, not FDA-approved: semaglutide shown at $49/month and tirzepatide at $99/month on embody's homepage (Nov 16, 2026), no insurance required.

Read full embody review
2
altRx logo

Excellent

9.4out of 10

Most Comprehensive GLP-1 Medication Access

Transparent pricingNo insurance required
  • Compounded GLP-1 from $89/mo, GLP-1 + GIP from $149/mo
  • Brand-name options too: Zepbound and Wegovy
  • Clinician-guided - physician, PA, or nurse practitioner
  • Free shipping (about 5-7 days)

from $89/month

Affordable GLP-1 program from $89/month - compounded semaglutide and tirzepatide plus brand-name options - with clinician-guided, self-pay care and no insurance required.

Read full altRx review

Can a manufacturer savings card or direct-pay price replace coverage?

Both manufacturers sell direct and both publish prices. The clearest example right now is Eli Lilly's Foundayo (orforglipron), the daily pill FDA-approved in April 2026: through LillyDirect it lists $149 a month at the 0.8 mg starting dose, $199 at 2.5 mg, $299 at 5.5 and 9 mg, and $349 at 14.5 and 17.2 mg, or $25 a month for commercially insured patients with its savings card - which can apply even when the plan itself declines to pay.

Savings cards for Zepbound and Wegovy exist too, with their own eligibility rules; we haven't verified their current terms, so check the manufacturer's page directly. Direct-pay still requires a prescription from a licensed clinician.

Does Medicare's $50 GLP-1 Bridge apply to you?

If you are on Medicare, the biggest change of 2026 applies to you. The Medicare GLP-1 Bridge is a CMS pilot that runs from July 1, 2026 through December 31, 2027 and charges eligible beneficiaries a flat $50 copay at the pharmacy for covered obesity drugs - the Wegovy pill and injection, the Zepbound KwikPen and Foundayo - with the copay staying at $50 as the dose rises.

Eligibility runs through clinical criteria and an approval step, and the program is explicitly temporary. Our GLP-1s after 65 page covers what we could verify and what to ask CMS or your Part D plan.

What does brand-name Zepbound or Wegovy cost for cash online?

If you want to stay on the exact product you were prescribed, several online providers sell it at a cash price. At our last verification, altRx lists Zepbound at $1,249 a month and Wegovy at $1,579, welludr Zepbound at $1,599, and Sprout Wegovy at $1,799; ro sells the Zepbound KwikPen from $299 for the first month, then $399-449, plus a membership - and because ro bills the pen as its own line item, a plan that still covers it can pay its share.

The full ladder, with what each route includes, is in what Zepbound costs online. This is the most expensive route on the page, and the one with no change in product.

Shop GLP-1 plans by product

The lowest published plans - cheapest first, conditions under each price.

What To Know Before Starting GLP-1 Treatment

Before starting GLP-1 treatment, it's important to understand a few key things. These medications require a prescription from a licensed clinician and aren't suitable for everyone. Some people may experience side effects, especially during the first few weeks as the body adjusts.

GLP-1s also tend to work best when combined with basic lifestyle habits like balanced nutrition and regular physical activity.

That's why choosing a provider that offers proper medical screening and ongoing follow-up support is essential for both safety and long-term success.

Woman preparing GLP-1 weight loss injection

Should you switch to a compounded version?

This is the route most people who lose coverage end up taking, because the arithmetic is stark: compounded semaglutide runs $41-$199 a month and compounded tirzepatide $71-$299 at the licensed providers in our price index, against $1,149-$1,799 for the brand drugs. The trade-off is just as stark and you should go in knowing it: a compounded product contains the same active ingredient but is prepared by a pharmacy rather than manufactured as an approved drug, it has no trials of its own, insurance never covers it, and the FDA has issued warning letters to dozens of telehealth companies in 2026 over how these products are marketed. Compounded vs brand-name lays out the difference honestly; 503A vs 503B and the 28-day rule explains how to check who actually makes it.

Can you keep your dose when you switch providers?

The question that worries people most is restarting from the lowest dose after months of titration. It is a clinical question, not a provider policy: a licensed clinician at the new provider reviews your current dose and history and decides whether to continue at that dose or step down, and most telehealth intake forms ask for it.

Bring your current prescription and the date of your last injection. The practical steps - timing the switch so you don't run out, what to send, what to ask - are in switching from Ozempic or another GLP-1.

What you should not do is bridge the gap with an unregulated "research peptide" bought without a prescription; here is why.

Which route first

In order of cost to you: appeal if the drug is still on your formulary; check your manufacturer's savings card and direct price; if you are on Medicare, the $50 Bridge; then decide between brand-name cash and a compounded switch based on your budget and your view of the trade-off. For the budget side, what $100-$200 a month gets you sorts every verified option by what you keep paying. None of this replaces your clinician's judgement about whether to continue treatment at all, and prices and program rules on this page change often enough that we date every one of them.

Ready to compare weight loss providers?

See how top providers stack up on pricing, medical support, and treatment options.

Medical disclaimer

This page is general information about GLP-1 weight-loss medications such as semaglutide and tirzepatide, published to help you compare services. It is not medical advice, it does not create a doctor-patient relationship, and it is not a substitute for a consultation with a licensed clinician who knows your history. Treatments Hub is not a medical provider, pharmacy or clinic and does not prescribe, sell or dispense medication. Do not start, stop or change any treatment because of something you read here, and do not delay seeking care; in an emergency call 911.

Semaglutide and tirzepatide carry an FDA boxed warning about thyroid C-cell tumours seen in rodents and are not for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, nor for use in pregnancy. Compounded versions sold by telehealth providers are prepared by state-licensed pharmacies and are not FDA-approved products. Where a review or post on this page mentions weight lost, that is one person's result and is not typical; results vary widely.

Medical and scientific statements on this site are checked against the sources linked on the page by our medical content reviewer, who does not choose providers or set prices. Prices, plans and customer reviews are each provider's published figures and customers' own words on the dates stated. We may earn a commission from provider links. The full medical and advertising disclaimer explains all of this in detail.

Sources & medical references

Treatment facts on this page are grounded in regulatory guidance and peer-reviewed research. Pricing and plan details come from each provider's published information. This content is for information only and is not medical advice - always consult a licensed clinician before starting treatment.

  1. 1.Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial) - New England Journal of Medicine, 2021
  2. 2.Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 trial) - New England Journal of Medicine, 2022
  3. 3.FDA Approves New Drug Treatment for Chronic Weight Management (semaglutide / Wegovy) - U.S. Food & Drug Administration, 2021
  4. 4.FDA Approves New Medication for Chronic Weight Management (tirzepatide / Zepbound) - U.S. Food & Drug Administration, 2023
  5. 5.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss - U.S. Food & Drug Administration
  6. 6.Human Drug Compounding (503A pharmacy standards) - U.S. Food & Drug Administration
  7. 7.Semaglutide Injection - drug information - MedlinePlus, U.S. National Library of Medicine (NIH)